NorthRock Partners’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

NorthRock Partners’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,521	Closed	-$66.6K	–	959
2025 Q1	$66.6K	Buy	1,521 +6	+0.4%	+$265	﹤0.01%	659
2024 Q4	$65.1K	Buy	1,515 +5	+0.3%	+$227	﹤0.01%	639
2024 Q3	$67K	Buy	1,510 +7	+0.5%	+$300	﹤0.01%	680
2024 Q2	$59.8K	Buy	1,503 +5	+0.3%	+$203	﹤0.01%	650
2024 Q1	$64.6K	Sell	1,498 -114	-7%	-$4.91K	﹤0.01%	647
2023 Q4	$67.1K	Buy	+1,612	New	+$61.1K	﹤0.01%	607

Other funds holding XPH

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

KWM

Kingsview Wealth Management Grants Pass, Oregon $8.25B AUM 24.8% 1-Year Est. Return

FCBT

First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return

Envestnet Portfolio Solutions Chicago, Illinois $20.9B AUM 19.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

NorthRock Partners's XPH Position: Q2 2025 in Review

NorthRock Partners sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q2 2025, closing a stake of 1,521 shares — an estimated $66.6K sold.

NorthRock Partners first reported a position in XPH in Q4 2023 and held it in 6 quarters. The position peaked at $67.1K in Q4 2023. 65 funds tracked by Wall St. Rank hold XPH as of Q2 2025.

NorthRock Partners reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q2 2025 after selling out during the quarter.
NorthRock Partners sold 1,521 State Street SPDR S&P Pharmaceuticals ETF shares in Q2 2025, an estimated $66.6K.
NorthRock Partners first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2023 and held it in 6 quarters.
NorthRock Partners's State Street SPDR S&P Pharmaceuticals ETF position peaked at $67.1K in Q4 2023.
65 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q2 2025.

Based on NorthRock Partners's 13F filing for Q2 2025, filed 25 Jul 2025.